

Michael D Staehler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4585616/publications.pdf>

Version: 2024-02-01

135
papers

10,511
citations

76326

40
h-index

32842

100
g-index

136
all docs

136
docs citations

136
times ranked

10783
citing authors

#	ARTICLE	IF	CITATIONS
1	Polyethylene glycol-coated collagen patch (hemopatch®) in open partial nephrectomy. <i>World Journal of Urology</i> , 2022, 40, 127-132.	2.2	0
2	Dynamics of urinary and respiratory shedding of Severe acute respiratory syndrome virus 2 (SARS-CoV-2) RNA excludes urine as a relevant source of viral transmission. <i>Infection</i> , 2022, 50, 635-642.	4.7	4
3	⁶⁸ Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1711-1720.	6.4	15
4	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , 2022, 61, 52-57.	1.8	0
5	Image-Guided Robotic Radiosurgery for the Treatment of Lung Metastases of Renal Cell Carcinoma—A Retrospective, Single Center Analysis. <i>Cancers</i> , 2022, 14, 356.	3.7	1
6	Propensity Score-Matched Analysis of Single Fraction Robotic Radiosurgery Versus Open Partial Nephrectomy in Renal Cell Carcinoma: Oncological Outcomes. <i>Cureus</i> , 2022, 14, e21623.	0.5	2
7	COVID-19 and financial toxicity in patients with renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 2559-2565.	2.2	11
8	Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1355-1362.	3.1	9
9	Patients'™ Perspective on Digital Technologies in Advanced Genitourinary Cancers. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 76-82.e6.	1.9	12
10	First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. <i>International Journal of Cancer</i> , 2021, 148, 950-960.	5.1	5
11	Everolimus after failure of one prior VEGF -targeted therapy in metastatic renal cell carcinoma: Final results of the MARC -2 trial. <i>International Journal of Cancer</i> , 2021, 148, 1685-1694.	5.1	7
12	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's™ Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Eur Urol Focus</i> . 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002 . [Epub ahead of print]. <i>European Urology Focus</i> , 2021, 7, 404-405.	3.1	3
13	Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 22-41.	5.4	33
14	Structured Reporting in the Characterization of Renal Cysts by Contrast-Enhanced Ultrasound (CEUS) Using the Bosniak Classification System—Improvement of Report Quality and Interdisciplinary Communication. <i>Diagnostics</i> , 2021, 11, 313.	2.6	3
15	Safety and Efficacy of Robotic Radiosurgery for Visceral and Lymph Node Metastases of Renal Cell Carcinoma: A Retrospective, Single Center Analysis. <i>Cancers</i> , 2021, 13, 680.	3.7	2
16	Immature Plasma Cell Myeloma Mimics Metastatic Renal Cell Carcinoma on 18F-PSMA-1007 PET/CT Due to Endothelial PSMA-Expression. <i>Diagnostics</i> , 2021, 11, 423.	2.6	1
17	Mapping Telemedicine in German Private Practice Urological Care: Implications for Transitioning beyond the COVID-19 Pandemic. <i>Urologia Internationalis</i> , 2021, 105, 650-656.	1.3	7
18	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). <i>Cancers</i> , 2021, 13, 2594.	3.7	2

#	ARTICLE	IF	CITATIONS
19	How the COVID-19 Pandemic Affects Sexual Behavior of Hetero-, Homo-, and Bisexual Males in Germany. <i>Sexual Medicine</i> , 2021, 9, 100380-100380.	1.6	15
20	Dynamic contrast-enhanced CT-derived blood flow measurements enable early prediction of long term outcome in metastatic renal cell cancer patients on antiangiogenic treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 13.e1-13.e8.	1.6	0
21	Stereotactic Radiotherapy for Oligoprogressive Disease: A New Frontier in Kidney Cancer. <i>European Urology</i> , 2021, 80, 701-702.	1.9	1
22	Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. <i>European Urology Oncology</i> , 2020, 3, 57-72.	5.4	62
23	Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC Registry. <i>International Journal of Cancer</i> , 2020, 146, 1307-1315.	5.1	6
24	Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT correlation with microvascular density. <i>European Radiology</i> , 2020, 30, 1-10.	4.5	57
25	Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI+CEUS) in Oncology. <i>Cancers</i> , 2020, 12, 2821.	3.7	14
26	Contrast-Enhanced Ultrasound (CEUS) for Follow-Up of Bosniak 2F Complex Renal Cystic Lesions: A 12-Year Retrospective Study in a Specialized European Center. <i>Cancers</i> , 2020, 12, 2170.	3.7	10
27	Contrast-Enhanced Ultrasound (CEUS) for the Evaluation of Bosniak III Complex Renal Cystic Lesions: A 10-Year Specialized European Single-Center Experience with Histopathological Validation. <i>Medicina (Lithuania)</i> , 2020, 56, 692.	2.0	10
28	Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?. <i>European Urology Focus</i> , 2020, 6, 1097-1103.	3.1	52
29	Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020, 3, 168-173.	5.4	25
30	Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 433-452.	5.4	43
31	Patient preferences and expectations of systemic therapy in renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 5083-5083.	1.6	6
32	Patient-reported outcomes on treatment-related side effects in renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 654-654.	1.6	4
33	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2020, 16, e1264-e1271.	2.9	16
34	Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 5084-5084.	1.6	0
35	Heterogeneity of PD-L1 expression between primary and metastatic bladder cancer tumors and therapeutic implications between the immune cell score and combined positivity score. <i>Journal of Clinical Oncology</i> , 2020, 38, e17041-e17041.	1.6	1
36	Fear of cancer recurrence among patients and survivors diagnosed with localized renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 649-649.	1.6	0

#	ARTICLE	IF	CITATIONS
37	CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.. Journal of Clinical Oncology, 2020, 38, TPS770-TPS770.	1.6	0
38	Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clinical Genitourinary Cancer, 2019, 17, e345-e355.	1.9	39
39	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. European Urology, 2019, 76, 151-156.	1.9	190
40	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus, 2019, 5, 958-969.	3.1	86
41	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	13.7	778
42	Optimized management of urolithiasis by coloured stent-stone contrast using dual-energy computed tomography (DECT). BMC Urology, 2019, 19, 29.	1.4	8
43	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scandinavian Journal of Urology, 2019, 53, 14-20.	1.0	15
44	Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. International Journal of Urology, 2019, 26, 532-542.	1.0	31
45	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. European Urology, 2019, 75, 799-810.	1.9	1,022
46	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 11.	2.8	11
47	Real-World Results from One Year of Therapy with Tivozanib. Kidney Cancer, 2019, 3, 235-239.	0.4	2
48	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. European Urology Oncology, 2019, 2, 141-149.	5.4	73
49	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6.	1.9	60
50	A Return to the Days of Radical Nephrectomy as the "Gold Standard" for Localized Renal Cell Carcinoma? Not So Fast. European Urology, 2019, 75, 546-547.	1.9	1
51	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). European Urology, 2019, 75, 261-264.	1.9	30
52	Metastatic papillary renal cell carcinoma in the era of targeted therapy " a retrospective study from three European academic centres. Acta Oncol ³ gica, 2019, 58, 306-312.	1.8	3
53	Distress in patients with renal cell carcinoma: a curious gap in knowledge. BJU International, 2019, 123, 208-209.	2.5	14
54	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. European Urology Focus, 2019, 5, 857-866.	3.1	67

#	ARTICLE	IF	CITATIONS
55	Comparison of efficacy and safety of checkpoint inhibitors in patients with genitourinary cancers aged below and above 75 years.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16101-e16101.	1.6	1
56	Patient perspectives on cytoreductive nephrectomy after CARMENA.. <i>Journal of Clinical Oncology</i> , 2019, 37, 658-658.	1.6	1
57	Fournier's Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature. <i>Cureus</i> , 2019, 11, e5778.	0.5	9
58	Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma. <i>Cureus</i> , 2019, 11, e4244.	0.5	2
59	Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 636-636.	1.6	2
60	Partial Nephrectomy in pT3a Tumors Less Than 7 cm in Diameter Has a Superior Overall Survival Compared to Radical Nephrectomy. <i>Cureus</i> , 2019, 11, e5781.	0.5	4
61	Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). <i>Cancer</i> , 2018, 124, 934-942.	4.1	125
62	New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?. <i>European Urology</i> , 2018, 73, 1-3.	1.9	4
63	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2018, 73, 311-315.	1.9	138
64	Systematic Review of the Management of Local Kidney Cancer Relapse. <i>European Urology Oncology</i> , 2018, 1, 512-523.	5.4	30
65	Cystic Appearance on Imaging Methods (Bosniak III-IV) in Histologically Confirmed Papillary Renal Cell Carcinoma is Mainly Characteristic of Papillary Renal Cell Carcinoma Type 1 and Might Predict a Relatively Indolent Behavior of Papillary Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2018, 101, 409-416.	1.3	3
66	A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. <i>European Urology</i> , 2018, 74, 849-851.	1.9	3
67	Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma. <i>European Urology</i> , 2018, 74, 842-843.	1.9	6
68	Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 805-809.	1.9	80
69	Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1101-e1115.	1.9	16
70	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1973-1980.	2.2	10
71	Emphysematous pyelonephritis: Case report and literature overview. <i>Urologia</i> , 2018, 85, 123-126.	0.7	8
72	An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 511-521.	3.8	61

#	ARTICLE	IF	CITATIONS
73	Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.. Journal of Clinical Oncology, 2018, 36, 4562-4562.	1.6	1
74	Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 4571-4571.	1.6	1
75	Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.. Journal of Clinical Oncology, 2018, 36, 576-576.	1.6	1
76	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). Journal of Clinical Oncology, 2018, 36, 578-578.	1.6	164
77	Imaging modalities used for follow-up of localized renal cell carcinoma (RCC) and subsequent effect on overall survival after recurrence: RECUR-database analysis.. Journal of Clinical Oncology, 2018, 36, 637-637.	1.6	2
78	Patients perspectives on adjuvant therapy in renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 644-644.	1.6	2
79	Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 589-589.	1.6	1
80	Development of a conversation aid tool for patients with localized renal cell carcinoma at high risk of recurrence.. Journal of Clinical Oncology, 2018, 36, 608-608.	1.6	0
81	S-TRAC trial: Sensitivity analyses of disease-free survival (DFS).. Journal of Clinical Oncology, 2018, 36, 633-633.	1.6	65
82	Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.. Journal of Clinical Oncology, 2018, 36, 4565-4565.	1.6	0
83	Patient-reported frustrations in renal cell carcinoma (RCC) care delivery: Results of a joint European Association of Urology (EAU)/KCCure survey.. Journal of Clinical Oncology, 2018, 36, 4570-4570.	1.6	0
84	Frustration and distress during treatment for advanced renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 47-47.	1.6	1
85	A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European Urology, 2017, 71, 426-436.	1.9	123
86	Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. European Urology, 2017, 71, 719-722.	1.9	69
87	Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer. European Radiology, 2017, 27, 2532-2537.	4.5	48
88	Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry. Clinical Genitourinary Cancer, 2017, 15, e209-e215.	1.9	46
89	Author Reply. Urology, 2016, 93, 122-123.	1.0	0
90	Nephron Sparing Surgery Associated With Better Survival Than Radical Nephrectomy in Patients Treated for Unforeseen Benign Renal Tumors. Urology, 2016, 93, 117-123.	1.0	17

#	ARTICLE	IF	CITATIONS
91	European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy. <i>European Urology</i> , 2016, 70, 705-706.	1.9	34
92	Long-term outcomes after resection of Stage IV cavoatrial tumour extension using deep hypothermic circulatory arrest. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 892-897.	1.4	13
93	Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 637-645.	2.4	56
94	Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. <i>European Urology</i> , 2016, 70, 265-280.	1.9	81
95	Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. <i>European Urology</i> , 2016, 69, 4-6.	1.9	85
96	Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>European Urology</i> , 2016, 69, 660-673.	1.9	412
97	Contribution of interleukin-22, a T cell secreted cytokine, to renal cell carcinoma progression and association with poor outcome in RCC patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4569-4569.	1.6	0
98	Single Fraction Radiosurgery for the Treatment of Renal Tumors. <i>Journal of Urology</i> , 2015, 193, 771-775.	0.4	84
99	EAU Guidelines on Renal Cell Carcinoma: 2014 Update. <i>European Urology</i> , 2015, 67, 913-924.	1.9	2,445
100	Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 339.e9-339.e15.	1.6	57
101	Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. <i>BMC Cancer</i> , 2015, 15, 303.	2.6	20
102	Local treatments for metastases of renal cell carcinoma: a systematic review. <i>Lancet Oncology</i> , The, 2014, 15, e549-e561.	10.7	265
103	A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4525-4525.	1.6	12
104	SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 393-393.	1.6	26
105	Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 469-469.	1.6	3
106	Survival of patients with papillary type II renal cell carcinoma treated with tyrosine-kinase inhibitors: A comparison with clear cell histologies.. <i>Journal of Clinical Oncology</i> , 2014, 32, 511-511.	1.6	1
107	Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study. <i>Onkologie</i> , 2013, 36, 95-100.	0.8	14
108	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.	27.0	1,648

#	ARTICLE	IF	CITATIONS
109	Combined Diffusion-Weighted, Blood Oxygen Level-Dependent, and Dynamic Contrast-Enhanced MRI for Characterization and Differentiation of Renal Cell Carcinoma. <i>Academic Radiology</i> , 2013, 20, 685-693.	2.5	25
110	Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 455-460.	1.6	104
111	Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 290-293.	1.6	36
112	Outcome Assessment of Patients With Metastatic Renal Cell Carcinoma Under Systemic Therapy Using Artificial Neural Networks. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 37-42.	1.9	18
113	Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. <i>American Journal of Surgery</i> , 2011, 202, 158-167.	1.8	93
114	Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. <i>BJU International</i> , 2011, 108, 673-678.	2.5	101
115	Contemporary Management of Small Renal Masses. <i>European Urology</i> , 2011, 60, 501-515.	1.9	164
116	The role of metastasectomy in metastatic renal cell carcinoma. <i>Nature Reviews Urology</i> , 2011, 8, 180-181.	3.8	20
117	Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation. <i>European Journal of Medical Research</i> , 2010, 15, 287.	2.2	30
118	Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. <i>World Journal of Urology</i> , 2010, 28, 543-547.	2.2	122
119	The growth rate of large renal masses opposes active surveillance. <i>BJU International</i> , 2010, 105, 928-931.	2.5	15
120	Single-Phase Dual-Energy CT Allows for Characterization of Renal Masses as Benign or Malignant. <i>Investigative Radiology</i> , 2010, 45, 399-405.	6.2	195
121	Profile of temsirolimus in the treatment of advanced renal cell carcinoma. <i>OncoTargets and Therapy</i> , 2010, 3, 191.	2.0	10
122	Plasma N-Terminal Pro-Brain Natriuretic Peptide as Prognostic Marker in Fatal Cardial Decompensation with Sunitinib Malate Therapy. <i>Urologia Internationalis</i> , 2010, 84, 119-121.	1.3	3
123	Tumor Infiltrated Hilar and Mediastinal Lymph Nodes are an Independent Prognostic Factor for Decreased Survival After Pulmonary Metastasectomy in Patients With Renal Cell Carcinoma. <i>Journal of Urology</i> , 2010, 184, 1888-1894.	0.4	52
124	Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 139-144.	1.6	27
125	Carcinoma of the Collecting Ducts of Bellini of the Kidney: Adjuvant Chemotherapy Followed by Multikinase Inhibition with Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 58-61.	1.9	29
126	Editorial Comment on: Identification of Stanniocalcin 2 as Prognostic Marker in Renal Cell Carcinoma. <i>European Urology</i> , 2009, 55, 678.	1.9	1

#	ARTICLE	IF	CITATIONS
127	Laser Therapy for Upper Urinary Tract Transitional Cell Carcinoma: Indications and Management. <i>European Urology</i> , 2009, 56, 65-71.	1.9	70
128	Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib [®] treatment. <i>Acta Ophthalmologica</i> , 2008, 86, 456-458.	1.1	33
129	Renal surgery in the elderly: morbidity in patients aged >75 years in a contemporary series. <i>BJU International</i> , 2008, 102, 684-687.	2.5	24
130	Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sunitinib Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. <i>Eur Urol</i> 2008;53:845-8. <i>European Urology</i> , 2008, 54, 950-951.	1.9	1
131	CyberKnife Radiosurgery for Malignant Spinal Tumors. <i>Spine</i> , 2008, 33, 2929-2934.	2.0	45
132	Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. <i>European Journal of Medical Research</i> , 2008, 13, 531-5.	2.2	8
133	Editorial Comment on: Associations of Single Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Gene with the Characteristics and Prognosis of Renal Cell Carcinomas. <i>European Urology</i> , 2007, 52, 1155.	1.9	0
134	Technical description, phantom accuracy, and clinical feasibility for fiducial-free frameless real-time image-guided spinal radiosurgery. <i>Journal of Neurosurgery: Spine</i> , 2006, 5, 303-312.	1.7	101
135	Therapeutic approaches in metastatic renal cell carcinoma. <i>BJU International</i> , 2005, 95, 1153-1161.	2.5	14